Lapril

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lapril

Quick Facts: Lapril (Enalapril)

Property Description
Active Ingredient Enalapril Maleate
Primary Form Oral tablets, Oral solution
Pharmacological Class ACE Inhibitor (Angiotensin-Converting Enzyme Inhibitor)
General Purpose Antihypertensive agent (supports blood pressure regulation)
Origin / Type Synthetic, Prodrug

The Defining Identity of Lapril: A Cardiovascular ACE Inhibitor

Lapril is a specific trade name for a prescription medication whose active compound is Enalapril Maleate. It is classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor, representing a primary pharmacological class of agents used for the management of cardiovascular conditions. Enalapril Maleate is recognized for its long-acting profile, which distinguishes it from earlier agents in its class and makes it suitable for chronic, sustained management.

Composition, Forms, and Origin of Enalapril

The core substance, Enalapril, is a synthetic, chemically derived compound categorized as a prodrug. This status means that the administered, inactive compound must undergo bioactivation in the liver to convert it into its potent working form, Enalaprilat. Lapril is most commonly available for the oral route of administration in the form of oral tablets and oral solution. The active metabolite, Enalaprilat, is additionally available as a solution for intravenous injection, a formulation used to provide flexibility for clinical use when oral administration is impractical.

General Purpose: How Lapril Supports Cardiovascular Health

The general purpose of Lapril is to act as a long-acting antihypertensive agent, supporting the circulatory system by reducing pressure and easing the heart’s workload. Its mechanism involves suppressing the system responsible for generating Angiotensin II, a substance that causes blood vessels to constrict. By inhibiting this process, the medication promotes vessel relaxation and widening (vasodilation), decreasing the overall resistance to blood flow. This action helps maintain the efficiency of the cardiovascular system and represents a standard therapeutic approach for managing circulatory needs.

Regulatory References

  1. Enalapril: MedlinePlus Drug Information

What side effects are possible with Lapril?

Possible Side Effects and Safety Information for Lapril (Enalapril)

This section outlines the officially documented adverse reactions and safety characteristics of Lapril, based strictly on government regulatory documents such as the FDA Prescribing Information and EMA Summary of Product Characteristics (SmPC).

Frequency-Classified Adverse Reactions

The adverse reactions are categorized by frequency of occurrence, as defined in official labeling:

Classification Examples of Reactions Affected System-Organ Class (SOC)
Very Common (ge 10%) Cough, Dizziness, Blurred vision, Asthenia (Lack of strength), Nausea Respiratory, Nervous, Eye, General, Gastrointestinal
Common (1% to <10%) Headache, Fatigue, Hypotension (Low blood pressure), Rash, Hyperkalaemia (High serum potassium) Nervous, General, Vascular, Skin, Metabolism

Serious Adverse Reactions and Restrictions

Official documents list critical warnings and severe adverse reactions that may occur:

  • Angioedema: Sudden swelling of the face, extremities, lips, tongue, glottis, and/or larynx is a risk and is noted to be potentially life-threatening due to the possibility of airway obstruction.
  • Fetal Toxicity: Use of Lapril during the second and third trimesters of pregnancy is strictly contraindicated due to the risk of injury and death to the developing fetus.
  • Acute Renal Failure: Deterioration of kidney function has been reported, particularly in patients with pre-existing severe heart failure or underlying renal artery stenosis.
  • Hepatic Failure: A rare syndrome of cholestatic jaundice progressing to fulminant hepatic necrosis has been associated with ACE inhibitors.

Population-Specific Safety Constraints

The label specifies several conditions where Lapril is contraindicated or requires particular caution:

  • Contraindication: Patients with a history of angioedema related to previous ACE inhibitor treatment or patients with hereditary/idiopathic angioedema.
  • Contraindication: Co-administration with aliskiren (a direct renin inhibitor) in diabetic patients.
  • Monitoring: Close monitoring of renal function, blood pressure, and serum potassium levels is mandated, especially at treatment initiation and in patients with known risk factors.

Time-Related Safety Patterns

The official labeling notes that symptomatic hypotension (excessive blood pressure drop) is most likely to occur following the initial dose in patients who are volume-depleted.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define Lapril (Enalapril) overdose primarily by the occurrence of Profound Hypotension (severely low blood pressure), which is an extension of the medication's intended effect.

Feature Official Regulatory Statement
Documented Manifestations The most likely manifestations are Profound Hypotension, often presenting with dizziness, lightheadedness, or fainting (syncope). Potential severe outcomes include Acute Renal Failure and Hyperkalemia (high serum potassium).
Emergency Actions Required Call emergency services (e.g., 911) if the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened. Immediate medical attention is mandated for any ingestion exceeding the prescribed dose.
Official Management Management is symptomatic and supportive. The documented procedure to counteract severe hypotension involves placing the individual in a supine position and administering an intravenous saline solution. For life-threatening cases, Hemodialysis is described as effective for clearing the active metabolite, Enalaprilat.
Monitoring and Risk Notes Close observation and frequent monitoring of blood pressure, renal function (e.g., BUN/Creatinine), and serum potassium levels are required. The half-life of the active metabolite is prolonged in patients with Glomerular Filtration Rate (GFR) le 30 mL/min.

The regulatory profile is structured to guide immediate response to severe cardiovascular consequences. The mandated emergency actions emphasize seeking urgent medical help when symptoms of profound hypotension, such as fainting or loss of consciousness, occur. Continuous monitoring is required until all symptoms are completely resolved, reflecting the potential for delayed or recurring hypotensive episodes.

Therapeutic Uses of Lapril

Lapril (Enalapril) is generally used for the sustained management of chronic cardiovascular conditions, offering key benefits across multiple related therapeutic domains. The medication is considered relevant for addressing conditions marked by increased physiological stress on the circulatory system.

The medication is commonly used to help with major indications including Essential Hypertension, Symptomatic Congestive Heart Failure, Asymptomatic Left Ventricular Dysfunction, and sometimes specific forms of proteinuric Chronic Kidney Disease.

Managing Chronic High Blood Pressure and Cardiac Risk

Lapril is generally considered relevant for addressing conditions marked by persistently elevated blood pressure. The use of Lapril supports the management of symptoms related to heightened physiological activity, and it may assist with managing major cardiovascular risk. This usage helps maintain a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes by easing distress related to symptoms that create noticeable physiological strain.

Supporting Compromised Heart Function and Kidney Health

The medication is commonly used to help with symptoms associated with Symptomatic Congestive Heart Failure and is relevant for the progression of Asymptomatic Left Ventricular Dysfunction. It supports the patient during difficult episodes by easing distress related to physical manifestations such as excessive fatigue and shortness of breath, assisting with maintaining functional stability. It is also used in situations involving certain distressing symptoms related to proteinuric Chronic Kidney Disease, helping to support general well-being during symptomatic phases.

Quick Fact: Symptom Support
Lapril supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Lapril (enalapril), an Angiotensin-Converting Enzyme (ACE) inhibitor, is strictly prohibited for use in several populations as defined by regulatory bodies. Eligibility is determined by excluding groups with a high risk of severe adverse outcomes or specific clinical states.

Contraindicated (Must Not Use) Restricted or Not Recommended
Pregnancy (second and third trimesters) due to risk of fetal injury/death. First Trimester of Pregnancy (use not recommended)
History of Angioedema (swelling) related to previous ACE inhibitor use, or hereditary/idiopathic angioedema. Breastfeeding (especially newborns or premature infants)
Hypersensitivity to enalapril or any other ACE inhibitor. Severe Renal Impairment (may require dose adjustment or be contraindicated in certain formulations)
Concomitant use with Sacubitril/Valsartan (must not be taken within 36 hours of each other). Geriatric Patients (use with caution, starting at a low dose due to potential kidney function changes)
Concomitant use with Aliskiren in patients with diabetes or moderate-to-severe kidney impairment. Volume-Depleted Patients (e.g., from high-dose diuretics or dialysis)

Use is generally accepted for all other populations requiring its approved indications, provided there are no other specific medical conditions that require special consideration or monitoring, such as existing liver or kidney disease.

What should I know about interactions with other medicines?

Lapril Interactions with Other Medicines and Products

This section details officially documented interaction patterns for Lapril (Enalapril Maleate), based strictly on government regulatory sources.


Formally Contraindicated Combinations

Certain combinations are officially prohibited due to the risk of severe adverse effects:

Interacting Substance Restriction/Reason
Sacubitril/Valsartan Co-administration is prohibited; a 36-hour washout period is required between doses due to the risk of angioedema.
Aliskiren Contraindicated in patients with Diabetes Mellitus or with renal impairment (GFR < 60 mL/ min/ 1.73 m^2) due to risks of hyperkalemia and hypotension.

Documented Pharmacodynamic Effects

Interactions that alter physiological response or substance levels include:

  • Potassium-Altering Agents: Co-administration with Potassium-Sparing Diuretics or Potassium Supplements increases the risk of severe hyperkalemia (elevated potassium levels).
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Concurrent use may reduce the blood pressure-lowering effect of Lapril and lead to deterioration of renal function, a risk heightened in the elderly or those with compromised kidney function.
  • Lithium: Lapril officially decreases the renal clearance of Lithium, potentially leading to increased serum levels and risk of toxicity.
  • Alcohol: Consumption of alcohol may increase the reported risk of dizziness associated with Lapril.

Food and Administration

Official regulatory sources note that food does not influence the absorption of Lapril.

Mechanism of Action

How Lapril Works

Lapril (Enalapril) is a prodrug that undergoes hepatic hydrolysis to form its active metabolite, enalaprilat. Enalaprilat acts primarily by interfering with the renin-angiotensin-aldosterone system (RAAS) and related pathways.

Enalaprilat is a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE). ACE functions as a peptidyl dipeptidase to catalyze the conversion of inactive angiotensin I to the vasoconstrictor angiotensin II. By inhibiting ACE, the formation of angiotensin II is reduced.

This diminution of circulating angiotensin II lessens the signaling that typically promotes systemic vascular constriction and aldosterone release. Since ACE is also identical to kininase II, the enzyme that degrades the vasodilator bradykinin, its inhibition contributes to elevated levels of this substance. The combined effect modifies physiological parameters, resulting in a decrease in overall peripheral vascular resistance and altered fluid excretion within the cardiovascular and renal pathways.

Dosage and Administration Information

How Lapril is Used: Official Administration Guidelines

This section describes the usage and administration principles for Lapril (Enalapril Maleate).


Administration Scope and Forms

Lapril is primarily administered via the oral route as tablets or a reconstituted solution. The active metabolite, Enalaprilat, is available for intravenous (IV) administration when oral use is not feasible. The oral tablets are available in multiple strengths, including 2.5 mg, 5 mg, 10 mg, and 20 mg. The medication may be taken with or without food.

Standard Dosing and Frequency

Indication Initial Dose Maximum Daily Dose
Hypertension (Adult) 5 mg once daily (or 2.5 mg if on a diuretic) 40 mg
Symptomatic Heart Failure (Adult) 2.5 mg twice daily 40 mg (in divided doses)

The standard schedule for uncomplicated hypertension is once daily. For conditions like heart failure, Lapril is typically administered in two divided doses daily. Dosage is subject to titration (gradual increase) over a period of 2 to 4 weeks, especially for heart failure, until the maintenance dose is reached.


Administration Rules and Adjustments

Patients with renal impairment require a lower initial dosage, typically 2.5 mg once daily when Creatinine Clearance is le 30 mL/min. Dosage for pediatric patients (above 1 month old) is determined on a weight-based calculation. If a scheduled dose is missed, the standard protocol is to skip the missed dose and resume the normal schedule; the dose should not be doubled.

Recent Clinical Evidence

Lapril: Recent Clinical Evidence

Research has explored the clinical profile of Lapril (an Angiotensin-Converting Enzyme [ACE] inhibitor) in managing hypertension and heart failure. Studies have evaluated the drug's effect on blood pressure reduction and its overall impact on cardiovascular outcomes.


Efficacy in Hypertension and Heart Failure

Pivotal randomized controlled trials (RCTs) established Lapril's role in the primary management of elevated blood pressure. These studies consistently demonstrated that Lapril was associated with a significant reduction in both systolic and diastolic blood pressure compared to placebo. A key finding from major trials in patients with heart failure was the observed reduction in all-cause mortality and hospitalizations related to heart failure, highlighting the drug's importance beyond simple blood pressure control.


Comparative Findings

Studies comparing Lapril to other antihypertensive agents have provided context on its use. In certain patient populations, trials have noted that Lapril demonstrated beneficial effects on cardiac function, including an increase in stroke volume and ejection fraction. However, when compared to specific other ACE inhibitors, some meta-analyses observed no significant differences in reducing blood pressure, with treatment selection often dependent on patient-specific factors such as tolerability.


Safety and Tolerability

Safety data from long-term clinical trials indicate that Lapril is generally tolerated by patients. The most commonly reported side effects associated with Lapril in these studies include cough, symptoms related to hypotension (low blood pressure), and fatigue. The incidence of cough was noted to be higher compared to placebo groups across several controlled studies. Long-term follow-up has provided data on the drug's safety profile over periods of 52 weeks and longer.

Frequently Asked Questions (FAQ)

Common questions about Lapril (FAQ)

Q: Is it common to feel a little dizzy when first starting Lapril?

Dizziness and lightheadedness are common side effects associated with Lapril. Official product information indicates that these symptoms are more likely to occur when treatment is first initiated or immediately following an increase in the dosage.

Q: Is Lapril safe to use if I have kidney issues?

Patients with impaired kidney function require close monitoring of specific renal parameters while taking Lapril. A dosage adjustment is typically required in these situations due to the potential for further kidney impairment, and prescribing information notes caution or contraindication in cases of severe impairment. Such decisions are specific to a patient’s condition.

Q: Does alcohol consumption affect the effectiveness or safety of Lapril?

Regulatory documents state that consuming alcohol can increase the blood pressure-lowering effect of Lapril. This interaction may result in an increased risk of dizziness or light-headedness while taking the medication.

Q: What should be done if I experience a potential side effect from Lapril?

Official guidance documents emphasize that severe or potentially life-threatening reactions require immediate medical attention (e.g., calling emergency services). Less severe symptoms warrant consultation with a healthcare professional.

Q: Can Lapril be taken at the same time as other heart medications?

Lapril is often used in combination with other cardiovascular medicines, such as diuretics (water pills). However, specific combinations with newer agents are strictly prohibited, and co-administration with other heart drugs requires individual evaluation by a healthcare provider.

Q: How long does Lapril usually take to start working?

Following an oral dose, the blood pressure-lowering activity typically begins within one hour. The maximum reduction in blood pressure is generally achieved approximately four to six hours after administration.

Q: Can Lapril be stopped abruptly, or should I talk to my doctor first?

Regulatory information advises that abruptly stopping Lapril has not been associated with a rapid, dangerous spike in blood pressure. However, discontinuing the medication may allow the condition being treated (hypertension) to reappear.

Q: Does taking Lapril affect my ability to drive?

Lapril may cause side effects such as dizziness, weakness, or blurred vision. Official documents caution that if these effects occur, especially when initiating the medicine or after a dose change, driving or operating heavy machinery may be impaired.

Q: Does Lapril cause weight gain or loss?

Lapril's official adverse reaction profile does not list isolated weight change as a common side effect. However, weight gain may be an indicator of a more serious complication, such as fluid retention or kidney issues, that warrants medical assessment.

Q: Are there any specific foods or drinks to avoid while on Lapril?

Official warnings recommend caution or the avoidance of potassium-containing salt substitutes. This is due to the potential risk of developing hyperkalemia, or dangerously high potassium levels, which is a condition that warrants close medical monitoring.

Q: What is the typical age range of people who use Lapril?

Lapril is approved for use in both pediatric patients (starting at one month of age) and adults. Regulatory documents provide specific weight-based dosing guidance for children and require caution and lower initial doses for older adults.

Q: Does Lapril require regular blood tests while taking it?

Yes, official monitoring guidelines mandate regular blood tests to check for changes in serum potassium and markers of renal function (kidney function). This monitoring is typically heightened when treatment is first initiated or the dosage is adjusted.

Q: Is Lapril a medication that I will have to take long-term?

Treatment with Lapril is typically considered long-term or chronic therapy. The medication is intended to help control the underlying condition by managing blood pressure and heart function, rather than providing a cure.

Q: Why is Lapril sometimes given together with a diuretic (water pill)?

The two medicine types are often combined because Lapril helps lower blood pressure by relaxing blood vessels, while the diuretic helps reduce blood pressure by assisting the kidneys in removing excess water and salt from the body.

Q: Are there any known long-term effects of taking Lapril?

Long-term data from clinical trials indicates the drug is generally tolerated. Potential effects during chronic use include a persistent dry cough and possible changes in potassium or kidney function that may necessitate ongoing medical assessment.

Q: How does Lapril relate to conditions like diabetes?

Official documents identify patients with diabetes mellitus as having a higher risk of developing hyperkalemia (elevated potassium levels) when taking Lapril and therefore necessitate close medical monitoring.

Q: Are headaches a temporary side effect of Lapril?

Official documents classify headaches as a common side effect of the medicine. However, regulatory information does not specifically state whether this symptom is temporary or tends to resolve over the course of treatment.

Q: Is Lapril considered a first-line treatment for its approved uses?

Lapril is a foundational medication for its approved uses in cardiovascular management. However, its recommended use as an initial therapy can vary depending on the patient's specific health profile and whether a combination product is being considered.

Q: Is Lapril safe for older adults to take?

Lapril can be used by older adults, but caution is advised because they may process drugs more slowly. Official guidance recommends starting with a lower dose or using a different dosing schedule.

Q: What kind of research has been done on Lapril and pregnancy?

Official documents issue a Boxed Warning regarding fetal toxicity. This warning is based on accumulated clinical data and reports related to the risk of serious injury and death to the developing fetus from drugs that act on the renin-angiotensin system.

Q: Why do doctors check blood pressure after starting Lapril?

Blood pressure is checked regularly, especially at the start of therapy, because Lapril can cause symptomatic hypotension (excessively low blood pressure). This effect is most likely to occur after the initial doses are administered.

Q: Does Lapril have a black box warning?

Yes, Lapril carries an official Boxed Warning (the highest level of warning required by the FDA). This warning specifically concerns the risk of fetal toxicity if the medication is taken during the second and third trimesters of pregnancy.

Q: Is it possible for Lapril to affect sleep?

While official lists of adverse reactions do not specifically list 'sleep' disorders, they do report the occurrence of central nervous system effects, such as dizziness and depression.

Q: How quickly does the body clear Lapril after the last dose?

The active compound of the medication (enalaprilat) has an effective half-life for accumulation of approximately 11 hours. This pharmacokinetic data describes the rate at which the body eliminates the medicine.

Q: Is Lapril meant to cure my condition, or just manage it?

Lapril is a chronic medication intended to control the underlying condition by managing blood pressure and heart function. It is important to understand that the medication is not a cure.

Q: Are women of childbearing age advised to take any precautions while using Lapril?

Due to the official risk of fetal injury, regulatory guidance states that Lapril should be discontinued as soon as possible if a pregnancy is detected. This highlights the need for caution in women of childbearing age.

Q: Are there any specific lifestyle changes recommended when taking Lapril?

Yes, treatment often includes recommendations for weight management and dietary changes as part of a comprehensive care plan. A reduction in sodium (salt) intake is particularly noted in official recommendations.

Q: Does taking Lapril influence the results of a standard medical test?

Yes, Lapril can cause elevations in certain lab values that are tested by a doctor. Notably, it can increase levels of serum potassium and serum creatinine, which are subject to medical monitoring.

Q: What is the longest period Lapril has been studied in clinical trials?

Published clinical studies related to the active ingredient (enalapril) have tracked its use in patients for extended periods. Evidence indicates that some observational follow-up studies have lasted for periods as long as 10 years in certain clinical settings.

Q: What are the official guidelines regarding Lapril use during breastfeeding?

Official guidance notes that Lapril may pass into breast milk and could potentially cause adverse effects in a breastfed infant. This requires a medical decision on whether to stop the medication or discontinue breastfeeding.

How should Lapril be stored and disposed of?

Storage and Disposal of Lapril

Official regulatory labeling dictates strict conditions to maintain the stability of Lapril (Enalapril Maleate) tablets.

Storage Requirements

Lapril must be stored at controlled room temperature, specifically between 20^circC and 25^circC (68^circF to 77^circF), with excursions permitted up to 30^circC. The medicine must be kept in its original container and maintained tightly closed to protect it from moisture. All Lapril must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Lapril must be disposed of according to local regulations. Regulators prefer the use of authorized drug take-back programs. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed container, and discarded with household trash. Lapril is not on the list of medicines recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lapril found in:

A-Z Index: